# Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

> **NCT06764368** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Chest Hospital** · enrollment: 39 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Adebrelimab + Apatinib

## Key facts

- **NCT ID:** NCT06764368
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06764368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06764368, "Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06764368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*